IDEXX Laboratories Valuation
| IX1 Stock | EUR 535.40 0.80 0.15% |
At this time, the firm appears to be overvalued. IDEXX Laboratories retains a regular Real Value of €455.09 per share. The prevalent price of the firm is €535.4. Our model calculates the value of IDEXX Laboratories from inspecting the firm fundamentals such as Operating Margin of 0.29 %, return on equity of 0.66, and Return On Asset of 0.26 as well as reviewing its technical indicators and probability of bankruptcy.
Price Book 34.7231 | Enterprise Value 44.2 B | Enterprise Value Ebitda 36.9986 | Price Sales 9.9339 | Forward PE 44.6429 |
Overvalued
Today
Please note that IDEXX Laboratories' price fluctuation is very steady at this time. Calculation of the real value of IDEXX Laboratories is based on 3 months time horizon. Increasing IDEXX Laboratories' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the IDEXX stock is determined by what a typical buyer is willing to pay for full or partial control of IDEXX Laboratories. Since IDEXX Laboratories is currently traded on the exchange, buyers and sellers on that exchange determine the market value of IDEXX Stock. However, IDEXX Laboratories' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 535.4 | Real 455.09 | Hype 534.53 | Naive 563.65 |
The real value of IDEXX Stock, also known as its intrinsic value, is the underlying worth of IDEXX Laboratories Company, which is reflected in its stock price. It is based on IDEXX Laboratories' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of IDEXX Laboratories' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of IDEXX Laboratories helps investors to forecast how IDEXX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of IDEXX Laboratories more accurately as focusing exclusively on IDEXX Laboratories' fundamentals will not take into account other important factors: IDEXX Laboratories Cash |
|
IDEXX Laboratories Total Value Analysis
IDEXX Laboratories is currently estimated to have takeover price of 44.16 B with market capitalization of 42.75 B, debt of 417.79 M, and cash on hands of 116.62 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the IDEXX Laboratories fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
44.16 B | 42.75 B | 417.79 M | 116.62 M |
IDEXX Laboratories Investor Information
About 96.0% of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 11.03. IDEXX Laboratories had not issued any dividends in recent years. The entity had 2:1 split on the 16th of June 2015. Based on the key indicators related to IDEXX Laboratories' liquidity, profitability, solvency, and operating efficiency, IDEXX Laboratories is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 573.5 M | 1.1 B |
|
| |||||
| Operating Income | 713.6 M | 1.3 B |
|
|
IDEXX Laboratories Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. IDEXX Laboratories has an asset utilization ratio of 118.34 percent. This implies that the Company is making €1.18 for each dollar of assets. An increasing asset utilization means that IDEXX Laboratories is more efficient with each dollar of assets it utilizes for everyday operations.IDEXX Laboratories Profitability Analysis
Based on IDEXX Laboratories' profitability indicators, IDEXX Laboratories may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess IDEXX Laboratories' ability to earn profits and add value for shareholders.Net Income | First Reported 2016-12-31 | Previous Quarter 294 M | Current Value 274.6 M | Quarterly Volatility 65.9 M |
For IDEXX Laboratories profitability analysis, we use financial ratios and fundamental drivers that measure the ability of IDEXX Laboratories to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well IDEXX Laboratories utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between IDEXX Laboratories's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of IDEXX Laboratories over time as well as its relative position and ranking within its peers.
IDEXX Laboratories Earnings per Share Projection vs Actual
By analyzing IDEXX Laboratories' earnings estimates, investors can diagnose different trends across IDEXX Laboratories' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for IDEXX Laboratories is based on EPS before non-recurring items and includes expenses related to employee stock options.IDEXX Laboratories Ownership Allocation
IDEXX Laboratories has a total of 79.85 Million outstanding shares. The majority of IDEXX Laboratories outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in IDEXX Laboratories to benefit from reduced commissions. Thereupon, third-party entities are subject to a different set of regulations than regular investors in IDEXX Laboratories. Please pay attention to any change in the institutional holdings of IDEXX Laboratories as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.IDEXX Laboratories Profitability Analysis
The company reported the revenue of 3.9 B. Net Income was 887.87 M with profit before overhead, payroll, taxes, and interest of 2.66 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates IDEXX Laboratories' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in IDEXX Laboratories and how it compares across the competition.
About IDEXX Laboratories Valuation
The stock valuation mechanism determines IDEXX Laboratories' current worth on a weekly basis. Our valuation model uses a comparative analysis of IDEXX Laboratories. We calculate exposure to IDEXX Laboratories's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of IDEXX Laboratories's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.7 B | 1.6 B |
IDEXX Laboratories Quarterly Retained Earnings |
|
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |